A case of acinar cell carcinoma of the pancreas.
- Author:
Kyu Young KIM
1
;
Hwa Jung LEE
;
Jun Ho JI
;
Jung Lim LEE
;
Won Sik LEE
;
Jong Hoon PARK
;
Kyung Rak SHON
Author Information
1. Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea. stemcell@hanafos.com
- Publication Type:Case Report
- Keywords:
Pancreas;
Carcinoma;
Acinar cell;
Capecitabine
- MeSH:
Abdominal Pain;
Acinar Cells;
Adult;
Carcinoma, Acinar Cell;
Deoxycytidine;
Fluorouracil;
Gastrectomy;
Hepatectomy;
Humans;
Neoplasm Metastasis;
Pancreas;
Pancreatectomy;
Pancreatic Neoplasms;
Positron-Emission Tomography;
Prognosis;
Recurrence;
Splenectomy;
Capecitabine
- From:Korean Journal of Medicine
2009;76(4):506-509
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acinar cell carcinoma of the pancreas is a rare tumor that constitutes 1~2% of all pancreatic cancers. The clinical and radiologic findings are inconclusive when diagnosing this disease. Acinar cell carcinoma progresses rapidly and metastasizes early, resulting in a poor prognosis. A 41-year-old man was admitted for abdominal pain. Abdominal computed tomography (CT) and positron emission tomography (PET)-CT showed a splenic mass involving the pancreatic tail with increased 18F-fluorodeoxyglucose (18F-FDG) uptake. A primary radical distal pancreatectomy and splenectomy were carried out. The pathology revealed acinar cell carcinoma of the pancreas. Three months later, a gastric recurrence was detected and a total gastrectomy was performed. Four months later, multiple hepatic metastases were found and a left hepatectomy was carried out. During treatment with capecitabine, no evidence of tumor progression was observed for 14 months. We report a case of metastatic pancreatic acinar cell carcinoma that did not progress for 14 months with capecitabine treatment.
